Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 15, 2018Journal of Clinical OncologyOpen Access

CheckMate-032 Study: Efficacy and Safety of Nivolumab and Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

YJYelena Y. JanjigianMemorial Sloan Kettering Cancer CenterJBJohanna C. BendellSarah CannonECEmiliano CalvoStart International

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Janjigian et al. (2018) studied this question.

synapsesocial.com/papers/6a7ca63203b6c06a674c77bbhttps://doi.org/10.1200/jco.2017.76.6212
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1PD-1 Blockade in Tumors with Mismatch-Repair Deficiency2015 · 9,608 citations
  2. 2Comprehensive molecular characterization of gastric adenocarcinoma2014 · 6,696 citations
  3. 3Lynch Syndrome Patients with Limited Family History Identified in a Laboratory Setting: A Descriptive Study2015 · 1,942 citations
  4. 4The clinicopathological and prognostic significance of PD-L1 expression in gastric cancer: a meta-analysis of 10 studies with 1,901 patients2016 · 151 citations
  5. 5Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study2017 · 513 citations